Higher-dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients
- 20 March 2000
- journal article
- clinical trial
- Published by Wiley in The Prostate
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Follow-up evaluation of a phase II prostate cancer vaccine trialThe Prostate, 1999
- GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trialThe Prostate, 1999
- Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatmentThe Prostate, 1999
- Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic diseaseThe Prostate, 1999
- Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptidesThe Prostate, 1998
- Patterns of care and rtog studies in prostate cancer: Long-term survival, hazard rate observations, and possibilities of cureInternational Journal of Radiation Oncology*Biology*Physics, 1994
- Patient Survival and Local Recurrence Rate Following Radical Prostatectomy for Prostatic CarcinomaJournal of Urology, 1986